中生製藥(01177.HK)治療惡性腫瘤藥獲上市批准

You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.

Hong Kong

Open Account

中生製藥(01177.HK)治療惡性腫瘤藥獲上市批准

阿思達克 01-03 16:33

中國生物製藥(01177.HK)公布，由集團開發的依維莫司片已獲得國家藥品監督管理局的上市批准，是首個國內因「首仿獲批+首個挑戰專利成功」獲得12個月市場獨佔期的產品。依維莫司為哺乳動物雷帕黴素靶蛋白(mTOR)的選擇性抑制劑，能通過干擾癌細胞的生長、分化和代謝，發揮抗腫瘤效應。該藥在腫瘤治療領域已經顯示出積極的作用，對多種惡性腫瘤的治療效果確切，其臨床價值得到充分肯定。

中國生物製藥(01177.HK)

Relevant Stocks

中國生物製藥(01177.HK)

Customer Service Hotline︰+852 3018 4526

Email︰cs@usmarthk.com

Address︰26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong

WhatsApp︰+852 5989 2641

Join the Community：

uSmart Securities Limited

is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907), provides securities trading services and is subject to its supervision.

Market News

中生製藥(01177.HK)治療惡性腫瘤藥獲上市批准

Services

About Us

Agreement Statement